148 related articles for article (PubMed ID: 19565926)
1. Tumor-targeted Salmonella typhimurium overexpressing cytosine deaminase: a novel, tumor-selective therapy.
King I; Itterson M; Bermudes D
Methods Mol Biol; 2009; 542():649-59. PubMed ID: 19565926
[TBL] [Abstract][Full Text] [Related]
2. A phase I trial of genetically modified Salmonella typhimurium expressing cytosine deaminase (TAPET-CD, VNP20029) administered by intratumoral injection in combination with 5-fluorocytosine for patients with advanced or metastatic cancer. Protocol no: CL-017. Version: April 9, 2001.
Cunningham C; Nemunaitis J
Hum Gene Ther; 2001 Aug; 12(12):1594-6. PubMed ID: 11529249
[TBL] [Abstract][Full Text] [Related]
3. Live bacteria as anticancer agents and tumor-selective protein delivery vectors.
Bermudes D; Zheng LM; King IC
Curr Opin Drug Discov Devel; 2002 Mar; 5(2):194-9. PubMed ID: 11926125
[TBL] [Abstract][Full Text] [Related]
4. Tumor-targeted Salmonella expressing cytosine deaminase as an anticancer agent.
King I; Bermudes D; Lin S; Belcourt M; Pike J; Troy K; Le T; Ittensohn M; Mao J; Lang W; Runyan JD; Luo X; Li Z; Zheng LM
Hum Gene Ther; 2002 Jul; 13(10):1225-33. PubMed ID: 12133275
[TBL] [Abstract][Full Text] [Related]
5. Pilot trial of genetically modified, attenuated Salmonella expressing the E. coli cytosine deaminase gene in refractory cancer patients.
Nemunaitis J; Cunningham C; Senzer N; Kuhn J; Cramm J; Litz C; Cavagnolo R; Cahill A; Clairmont C; Sznol M
Cancer Gene Ther; 2003 Oct; 10(10):737-44. PubMed ID: 14502226
[TBL] [Abstract][Full Text] [Related]
6. Optimization of tumor-targeted gene delivery by engineered attenuated Salmonella typhimurium.
Mei S; Theys J; Landuyt W; Anne J; Lambin P
Anticancer Res; 2002; 22(6A):3261-6. PubMed ID: 12530073
[TBL] [Abstract][Full Text] [Related]
7. The oncolytic effect of recombinant vesicular stomatitis virus is enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene.
Porosnicu M; Mian A; Barber GN
Cancer Res; 2003 Dec; 63(23):8366-76. PubMed ID: 14678998
[TBL] [Abstract][Full Text] [Related]
8. Biodistribution and genetic stability of the novel antitumor agent VNP20009, a genetically modified strain of Salmonella typhimurium.
Clairmont C; Lee KC; Pike J; Ittensohn M; Low KB; Pawelek J; Bermudes D; Brecher SM; Margitich D; Turnier J; Li Z; Luo X; King I; Zheng LM
J Infect Dis; 2000 Jun; 181(6):1996-2002. PubMed ID: 10837181
[TBL] [Abstract][Full Text] [Related]
9. Antitumor therapeutic effects of Salmonella typhimurium containing Flt3 Ligand expression plasmids in melanoma-bearing mouse.
Yoon WS; Choi WC; Sin JI; Park YK
Biotechnol Lett; 2007 Apr; 29(4):511-6. PubMed ID: 17235489
[TBL] [Abstract][Full Text] [Related]
10. Antitumour activity of Salmonella typhimurium VNP20047 in B16(F10) murine melanoma model.
Jazowiecka-Rakus J; Szala S
Acta Biochim Pol; 2004; 51(3):851-6. PubMed ID: 15448746
[TBL] [Abstract][Full Text] [Related]
11. Salmonella-mediated tumor-targeting TRAIL gene therapy significantly suppresses melanoma growth in mouse model.
Chen J; Yang B; Cheng X; Qiao Y; Tang B; Chen G; Wei J; Liu X; Cheng W; Du P; Huang X; Jiang W; Hu Q; Hu Y; Li J; Hua ZC
Cancer Sci; 2012 Feb; 103(2):325-33. PubMed ID: 22054098
[TBL] [Abstract][Full Text] [Related]
12. Salmonella and cancer: from pathogens to therapeutics.
Chorobik P; Czaplicki D; Ossysek K; Bereta J
Acta Biochim Pol; 2013; 60(3):285-97. PubMed ID: 23828775
[TBL] [Abstract][Full Text] [Related]
13. Direct and bystander killing of sarcomas by novel cytosine deaminase fusion gene.
Ramnaraine M; Pan W; Goblirsch M; Lynch C; Lewis V; Orchard P; Mantyh P; Clohisy DR
Cancer Res; 2003 Oct; 63(20):6847-54. PubMed ID: 14583482
[TBL] [Abstract][Full Text] [Related]
14. Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.
Miller CR; Williams CR; Buchsbaum DJ; Gillespie GY
Cancer Res; 2002 Feb; 62(3):773-80. PubMed ID: 11830532
[TBL] [Abstract][Full Text] [Related]
15. Synergistic antitumor efficacy of suicide/ePNP gene and 6-methylpurine 2'-deoxyriboside via Salmonella against murine tumors.
Fu W; Lan H; Li S; Han X; Gao T; Ren D
Cancer Gene Ther; 2008 Jul; 15(7):474-84. PubMed ID: 18437183
[TBL] [Abstract][Full Text] [Related]
16. Evaluation of the acute and subchronic toxic effects in mice, rats, and monkeys of the genetically engineered and Escherichia coli cytosine deaminase gene-incorporated Salmonella strain, TAPET-CD, being developed as an antitumor agent.
Lee KC; Zheng LM; Margitich D; Almassian B; King I
Int J Toxicol; 2001; 20(4):207-17. PubMed ID: 11563416
[TBL] [Abstract][Full Text] [Related]
17. Random mutagenesis and selection of Escherichia coli cytosine deaminase for cancer gene therapy.
Mahan SD; Ireton GC; Knoeber C; Stoddard BL; Black ME
Protein Eng Des Sel; 2004 Aug; 17(8):625-33. PubMed ID: 15381761
[TBL] [Abstract][Full Text] [Related]
18. Cytotoxic effect of replication-competent adenoviral vectors carrying L-plastin promoter regulated E1A and cytosine deaminase genes in cancers of the breast, ovary and colon.
Akbulut H; Zhang L; Tang Y; Deisseroth A
Cancer Gene Ther; 2003 May; 10(5):388-95. PubMed ID: 12719708
[TBL] [Abstract][Full Text] [Related]
19. Adenovirus-mediated GM-CSF gene and cytosine deaminase gene transfer followed by 5-fluorocytosine administration elicit more potent antitumor response in tumor-bearing mice.
Cao X; Ju DW; Tao Q; Wang J; Wan T; Wang BM; Zhang W; Hamada H
Gene Ther; 1998 Aug; 5(8):1130-6. PubMed ID: 10326037
[TBL] [Abstract][Full Text] [Related]
20. Improvement of antitumor activity by gene amplification with a replicating but nondisseminating adenovirus.
Bourbeau D; Lau CJ; Jaime J; Koty Z; Zehntner SP; Lavoie G; Mes-Masson AM; Nalbantoglu J; Massie B
Cancer Res; 2007 Apr; 67(7):3387-95. PubMed ID: 17409449
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
